Clinical Trials
Sep 27, 2026 · 1 min read · 26,976 views
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
A
Aiden Brooks
Editorial · Sep 27, 2026
Plus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The
← Previous
Roche kidney drug's Phase 3 win sets up path to accelerated approval
Next →
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Related Reading
Clinical Trials
Roche kidney drug's Phase 3 win sets up path to accelerated approval
Sep 28, 2026
Clinical Trials
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Sep 27, 2026
Clinical Trials
Celldex falls on safety concern, even as chronic hives drug succeeds in Phase 3 trials
Sep 26, 2026